Data on Lung Cancer Reported by Jingjing Lv and Colleagues (Health insurance as a moderator in the relationship between financial toxicity and medical cost-coping behaviors: Evidence from patients with lung cancer in China): Oncology – Lung Cancer

2024 JAN 12 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Oncology - Lung Cancer is the subject of a report. According to news reporting originating from Jinan, People’s Republic of China, by NewsRx correspondents, research stated, “This study investigates the relationship between financial toxicity and medical cost-coping behaviors (MCCB) in Chinese patients with lung cancer, with a particular focus on the moderating role of health insurance. We surveyed 218 patients with lung cancer and assessed their Comprehensive Score for Financial Toxicity (COST) and self-reported MCCB.”

Our news editors obtained a quote from the research, “Patients were categorized into Urban Employee’s Basic Medical Insurance (UEBMI) group and Urban-Rural Resident Basic Medical Insurance Scheme (URRBMI) groups by their medical insurance, and matched for socioeconomic, demographic, and disease characteristics via propensity score. Significant different characteristics were noted between UEBMI patients and URRBMI patients. Patients with UEBMI had higher COST scores but lower levels of MCCB compared to URRBMI patients in the original dataset. After data matching, multivariate logit regression analysis showed that better financial toxicity was associated with lower levels of MCCB (OR = 0.95, 95% CI: 0.92-0.99). Health insurance type did not have a direct association with cost-coping behaviors, but an interaction was observed between health insurance type and financial toxicity. Among patients with URRBMI, better financial toxicity was associated with lower levels of cost-coping behaviors (OR = 0.89, 95% CI: 0.83-0.95). Patients with UEBMI had a lower probability of engaging in any cost-coping behaviors in situations of worse financial toxicity compared to patients with URRBMI. The findings suggest that financial toxicity is correlated with MCCB in Chinese patients with lung cancer. The type of health insurance, specifically UEBMI and URRBMI, plays a moderating role in this relationship.”

According to the news editors, the research concluded: “Understanding these dynamics is essential for developing targeted interventions and policies to mitigate financial toxicity and improve patients’ management of medical costs.”

For more information on this research see: Health insurance as a moderator in the relationship between financial toxicity and medical cost-coping behaviors: Evidence from patients with lung cancer in China. Cancer Medicine, 2024. Cancer Medicine can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - http://www.wiley.com/; Cancer Medicine - http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2045-7634)

The news editors report that additional information may be obtained by contacting Jingjing Lv, Expanded Program Immunization Division of Shandong Provincial Center for Disease Control and Prevention, Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Jinan, People’s Republic of China. Additional authors for this research include Yongchun Cui, Xiaoyu Hu and Dawei Zhu.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1002/cam4.6911. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Cancer Medicine is: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)